Interstitial Lung Diseases: New Treatments and Future Directions

Dear Colleagues,

Interstitial lung diseases (ILDs) are a diverse group of disorders that lead to progressive lung fibrosis and significant morbidity. These diseases present a considerable challenge in clinical practice due to their heterogeneity and complex pathophysiology. This Special Issue, titled "Interstitial Lung Diseases: New Treatments and Future Directions", will focus on recent breakthroughs in the treatment of ILDs, highlighting novel therapeutic approaches and emerging treatment strategies aimed at improving patient outcomes.

Key topics of interest will include the following:

• The latest advancements in pharmacologic treatments, such as antifibrotic agents, immunomodulators, and biologic therapies;
• The role of precision medicine in ILDs, exploring individualized treatment approaches based on genetic, phenotypic, and environmental factors;
• Investigations into novel drug mechanisms and combination therapies designed to halt or reverse disease progression;
• The potential impact of emerging treatments, including regenerative medicine, stem cell therapy, and gene therapies, in the future management of ILDs;
• Future challenges in the long-term management and development of patient-centered care strategies.

This Special Issue aims to provide an in-depth exploration of the evolving landscape of ILD treatment, offering insights into both established and emerging therapies. We invite contributions that focus on innovative treatment strategies, the scientific basis for these interventions, and their potential to transform the management of ILDs.

Dr. Justyna Fijołek
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.